PARTNER NEWS:Thu, Mar 14, 8:40 AM, Zacks
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Thu, Feb 22, 9:29 AM, Zacks
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.